Custodiol-N与Custodiol在择期冠状动脉旁路移植术患者中的前瞻性随机双盲多中心III期试验
该研究为前瞻性随机双盲非劣效性试验,在择期冠状动脉旁路移植术患者中比较Custodiol-N与Custodiol的心脏保护作用,主要终点为术后24小时内CK-MB曲线下面积。纳入101例患者后因主要非劣效性终点达到而提前终止,两组CK-MB和肌钙蛋白T曲线下面积相似,Custodiol-N组峰值CK-MB显著更低。结论认为Custodiol-N安全且提供与Custodiol相似的心脏保护。
要点
- Custodiol-N与Custodiol在择期冠状动脉旁路移植术中提供相似的心脏保护。
- Custodiol-N组峰值CK-MB显著低于Custodiol组( superiority P < 0.03)。
- 试验纳入101例患者后因主要非劣效性终点达到而按方案提前终止。
核心结论
- Custodiol-N安全,并提供与已建立的HTK-Custodiol溶液相似的心脏保护。
- Custodiol-N组在全分析集中峰值CK-MB水平显著降低,可能提示在冠状动脉旁路移植术背景下对缺血/再灌注损伤有益处。
研究设计与样本
- 前瞻性随机双盲非劣效性试验,在择期冠状动脉旁路移植术患者中比较Custodiol-N与Custodiol。
- 主要终点为术后24小时内肌酸激酶心肌同工酶(CK-MB)曲线下面积(AUC)。
- 次要终点包括峰值CK-MB和肌钙蛋白T、肌钙蛋白T释放的AUC、心脏指数、累积儿茶酚胺剂量、重症监护室停留时间和死亡率。
- 纳入101例患者后因主要非劣效性终点达到而按方案提前终止试验。
主要发现
- CK-MB AUC为Custodiol组878±549 h U/l vs Custodiol-N组779±439 h U/l,非劣效性P < 0.001。
- 肌钙蛋白T AUC为Custodiol组12990±8347 h pg/ml vs Custodiol-N组13498±6513 h pg/ml,非劣效性P < 0.001。
- 峰值CK-MB为Custodiol组52±40 U/l vs Custodiol-N组42±28 U/l,优效性P < 0.03,Custodiol-N组显著更低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: HTK-Solution (Custodiol) is a well-established cardioplegic and organ preservation solution. We currently developed a novel HTK-based solution, Custodiol-N, which includes iron chelators to reduce oxidative injury, as well as l-arginine, to improve endothelial function. In this first-in-human study, Custodiol-N was compared to Custodiol in patients undergoing elective coronary artery bypass surgery. The aim of this comparison was to evaluate the safety and ability of Custodiol-N to protect cardiac tissue. METHODS: The study was designed as a prospective randomized double-blind non-inferiority trial. Primary end point was area under the curve (AUC) of creatine kinase muscle-brain (CK-MB) within the first 24 h after surgery. Secondary end points included peak CK-MB and troponin-T and AUC of troponin-T release, cardiac index, cumulative catecholamine dose, intensive care unit stay and mortality. All values in the abstract are given as mean ± SD, P < 0.05 was considered statistically significant. RESULTS: Early termination of the trial was performed per protocol as the primary non-inferiority end-point was reached after inclusion of 101 patients. CK-MB AUC (878±549 vs 779±439 h U/l, non-inferiority P < 0.001, Custodiol vs Custodiol-N) and troponin-T AUC (12990±8347 vs 13498±6513 h pg/ml, noninferiority P < 0.001, Custodiol vs Custodiol-N) were similar in both groups. Although the trial was designed for non-inferiority, peak CK-MB (52±40 vs 42±28 U/l, superiority P < 0.03, Custodiol vs Custodiol-N) was significantly lower in the Custodiol-N group. CONCLUSIONS: This study shows that Custodiol-N is safe and provides similar cardiac protection as the established HTK-Custodiol solution. Significantly reduced peak CK-MB levels in the Custodiol-N group in the full analysis set may implicate a beneficial effect on ischaemia/reperfusion injury in the setting of coronary bypass surgery.
引用
- Szabó G, Brlecic P, Loganathan S, et al. Custodiol-N versus Custodiol: a prospective randomized double-blind multicentre phase III trial in patients undergoing elective coronary bypass surgery. Eur J Cardiothorac Surg. 2022. PMID: 35579350. doi:10.1093/ejcts/ezac287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。